Julia Brinkmann
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.
Journal: Future oncology (London, England)
Published: July 27, 2026
Sasanlimab taken together with Bacillus Calmette-Guérin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: May 24, 2026
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Journal: Nature medicine
Published: July 21, 2025
Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.
Journal: The patient
Published: June 11, 2025
On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC.
Journal: Oncology and therapy
Published: January 29, 2025
Economic Impact of Bladder Cancer in the USA.
Journal: PharmacoEconomics - open
Published: July 15, 2024
Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.
Journal: Molecular diagnosis & therapy
Published: October 17, 2021
Activation of the aryl hydrocarbon receptor sensitises human keratinocytes for CD95L- and TRAIL-induced apoptosis.
Journal: Cell death & disease
Published: September 07, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026